AzurRx (AZRX) Corporate Media Kit

24 Trial Design • N = 11 CP patients • 2-week wash-out period; ascending doses of MS1819, with the highest daily dose being 2.2 grams per day Primary endpoints: Safety and CFA change from baseline Secondary endpoints: Number of bowel movements, stool consistency and steatorrhea, also showed statistically significant and clinically meaningful improvements with MS1819 treatment. Results • Statistically significant improvements in CFA on an ITT (Intent To Treat) and PP (Per Protocol) basis. • Favorable safety profile with no serious adverse events MS1819 Phase 2 Chronic Pancreatitis Trial (Completed 2018)